A California woman has filed a Taxotere alopecia lawsuit against the makers of her chemotherapy drug.

Plaintiff Soinia B. was treated with Taxotere and docetaxel injection between March 1 and June 14, 2007. While her short-form complaint connected to Multidistrict Litigation (MDL) No. 2740 didn’t indicate the condition for which this was administered, Taxotere is a frequent choice for the treatment of breast cancer.

Shortly after completing treatment, she alleges disfiguring and permanent alopecia, or hair loss, ensued. Because of the disfiguring and permanent alopecia, she was moved to file a Taxotere products liability lawsuit on Nov. 20, 2017.

Soinia was treated with the allegedly injurious drug as a citizen and resident of the State of California. She brings her formal complaint against Sanofi U.S. Services Inc., formerly known as Sanofi-Aventis U.S. Inc., and Sanofi-Aventis U.S., LLC.

According to the long-form complaint in the Taxotere MDL, the named defendants allegedly were aware of the tendency of a certain percentage of Taxotere recipients to develop disfiguring and permanent alopecia.

Plaintiffs claim the manufacturers and distributors of this chemotherapy drug did nothing despite this knowledge to warn the public or medical professional community and in fact did their best to hide the heinous side effect.

A Clinical Trial by Sanofi

In 1998, Sanofi sponsored a clinical trial known as GEICAM 9805. It ran between June 1999 and March 2003 with 1060 recipients receiving Taxotere or a competitor drug.

By two years after its completion, it was clear that roughly 10% of Taxotere patients developed disfiguring and permanent alopecia for up to a decade or longer. Plaintiffs claim this result was never made public on Taxotere’s label.

The Plaintiff’s Allegations

The plaintiff complains that the disfiguring and permanent alopecia she has experienced has created severe and debilitating emotional distress for her. She alleges she has been made to suffer mental anguish and expects this mental state to continue indefinitely.

Soinia is bringing the following counts against the named defendants: Count One—Strict Products Liability, Failure to Warn; Count Three–Negligence; Count Four—Negligent Misrepresentation; Count Five—Fraudulent Misrepresentation; Count Six—Fraudulent Concealment; and Count Seven—Fraud and Deceit.

In addition, the defendants stand accused by the plaintiff of intentional infliction of emotional distress by their allegedly extreme and outrageous conduct. She seeks an award of punitive damages in light of this accusation.

Soinia is asking for compensatory and special damages in an amount within the jurisdiction of the court according to evidence providing during the trial so requested. She is also asking for consideration of her loss of income and earning power, and her medical expenses from the past and into the future when the amount of damages are determined. She requests a trial by jury.

This Disfiguring and Permanent Alopecia Lawsuit is Case No. 2:17-cv-12774-KDE-MBN in U.S. District Court, Eastern District of Louisiana. This Case is part of MDL No. 2740, In re: Taxotere (Docetaxel) Products Liability Litigation.